Independent Portfolio Consultants’s Ligand Pharmaceuticals LGND Stock Holding History

Independent Portfolio Consultants’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$143K	Sell	1,887 -606	-24%	-$42.4K	0.06%	351
2017 Q1	$165K	Buy	2,493 +24	+1%	+$1.58K	0.06%	361
2016 Q4	$156K	Sell	2,469 -56	-2%	-$3.53K	0.05%	365
2016 Q3	$161K	Buy	2,525 +104	+4%	+$7.64K	0.05%	376
2016 Q2	$180K	Buy	2,421 +2,261	+1,413%	+$168K	0.06%	354
2016 Q1	$11K	Buy	160 +48	+43%	+$2.92K	﹤0.01%	714
2015 Q4	$8K	Buy	+112	New	+$6.92K	﹤0.01%	725
2015 Q3	–	Sell	-104	Closed	-$7K	–	838
2015 Q2	$7K	Buy	+104	New	+$5.67K	﹤0.01%	790
2014 Q4	–	Sell	-4,609	Closed	-$135K	–	842
2014 Q3	$135K	Buy	+4,609	New	+$153K	0.04%	513

Other funds holding LGND

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

SCM

Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Independent Portfolio Consultants's LGND Position: Q2 2017 in Review

Independent Portfolio Consultants reduced its Ligand Pharmaceuticals (LGND) stake by 24% in Q2 2017, selling an estimated $42.4K and leaving 1,887 shares worth $143K. The position accounts for 0.06% of the portfolio, ranked #351.

Independent Portfolio Consultants first reported a position in LGND in Q3 2014 and has held it in 9 quarters since. The position peaked at $180K in Q2 2016. 266 funds tracked by Wall St. Rank hold LGND as of Q2 2017.

Independent Portfolio Consultants held 1,887 shares of Ligand Pharmaceuticals worth $143K as of Q2 2017.
Independent Portfolio Consultants sold 606 Ligand Pharmaceuticals shares in Q2 2017, an estimated $42.4K.
Ligand Pharmaceuticals made up 0.06% of Independent Portfolio Consultants's portfolio in Q2 2017, its #351 holding.
Independent Portfolio Consultants first reported a position in Ligand Pharmaceuticals in Q3 2014 and has held it in 9 quarters since.
Independent Portfolio Consultants's Ligand Pharmaceuticals position peaked at $180K in Q2 2016.
266 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2017.

Based on Independent Portfolio Consultants's 13F filing for Q2 2017, filed 6 Jul 2017.